Philip Morris International (PM) Q2 2025: Smoke-Free Revenue Jumps 17%, Margin Expansion Drives EPS Upgrade
Philip Morris International’s Q2 2025 saw smoke-free products surge, with gross margin expansion and pricing power offsetting modest combustible declines. Management raised full-year EPS guidance as smoke-free momentum and cost discipline outpaced headwinds in key legacy markets. Investors should watch the ramp of U.S. Zyn and the ILUMA launch for further upside signals.
Summary
- Smoke-Free Acceleration: Multi-category smoke-free products outpaced combustibles, expanding gross margin and user base.
- Resilient Combustibles: Pricing and efficiency offset volume softness, supporting profit growth even as volumes trend down.
- Guidance Raised: Upgraded EPS outlook on smoke-free momentum and operational leverage despite regulatory and FX volatility.
Performance Analysis
Q2 2025 marked a decisive step-change for Philip Morris International (PMI), with smoke-free products—encompassing IQOS (heated tobacco), Zyn (nicotine pouches), and Veve (eVapor)—delivering over $4 billion in net revenues and organic growth of 17.3% in H1. Gross margin for smoke-free reached 70%, now exceeding combustibles by 4.5 percentage points, a testament to scale, mix, and pricing discipline. The company’s top-line grew 6.8% organically (over 8% excluding Indonesia’s technical impact), while adjusted operating income (OI) jumped 14.9% organically, with margin expansion across all categories.
Combustible volumes declined modestly, in line with management’s long-term low single-digit decline expectation, but robust pricing (+7.7% in H1) and cost efficiencies drove profit growth. Temporary supply chain disruptions in Turkey and illicit market growth in Indonesia weighed on combustibles, but these were contained. Adjusted diluted EPS grew 20% in Q2, aided by favorable currency impact and margin progression. The smoke-free user base grew by approximately five million year-over-year, reaching 41.5 million, and the company is on track for its fifth consecutive year of total shipment volume growth.
- Smoke-Free Outperformance: All three categories—IQOS, Zyn, and Veve—delivered double-digit or higher volume growth, with Zyn’s U.S. recovery a standout.
- Margin Expansion: Gross margin expansion was driven by smoke-free scale, positive mix, and pricing, with cost savings exceeding $500 million year-to-date.
- Combustible Stability: Despite volume contraction, profit and margin grew, highlighting the resilience of PMI’s legacy business model.
PMI’s multi-engine growth model is now increasingly weighted toward smoke-free profitability, with combustibles providing steady cash flow and pricing upside. The company is executing on both innovation and operational discipline, setting the stage for continued EPS growth and cash generation.
Executive Commentary
"Top-line dynamism from our smoke-free portfolio, which reached a record $4 billion in net revenues, coupled with margin improvements across our business, drove strong double-digit adjusted diluted earning per share growth in both constant currency and dollar terms."
Emmanuel Barbot, Chief Financial Officer
"Our multi-category approach is built on the strength of the brand and commercial presence of IQOS, which remains our core smoke-free product growth engine. We continue to be laser-focused on maximizing the growth of IQOS over time, with the deployment of Zyn and Veve under its umbrella, offering complementary opportunities to fully transition legal-age nicotine users from cigarettes to SFPs."
Emmanuel Barbot, Chief Financial Officer
Strategic Positioning
1. Multi-Category Smoke-Free Expansion
PMI’s multi-category strategy—offering IQOS (heated tobacco), Zyn (nicotine pouches), and Veve (eVapor)—is driving user acquisition and margin accretion. Smoke-free products are now in 97 markets, with 20 markets offering all three categories. This approach leverages brand strength and commercial infrastructure, enabling cross-category switching and higher consumer lifetime value.
2. U.S. Zyn Recovery and Growth
Zyn’s U.S. off-tech (retail sell-out) growth reaccelerated to 36% in June, following supply normalization and the resumption of promotional activity. PMI is now “pulling all levers” to maximize share, with expanded capacity and renewed commercial investment. The company targets 800 to 840 million cans shipped in 2025, with H2 growth expected to be driven by full promotional ramp and retail availability.
3. IQOS Innovation and Global Rollout
IQOS remains the core growth engine, with the ILUMA device now in over 30 markets and strong momentum in Europe, Japan, and new geographies like Indonesia. Device and consumable innovation (e.g., Livia, Delia, Rivenpack) is supporting premiumization and share gains, especially as regulatory headwinds like the EU flavor ban subside.
4. Combustible Cash Flow and Resilience
While combustible volumes are forecast to decline around 2% for the year, pricing (+6% to +7% full-year forecast) and cost discipline are sustaining profit growth. The business remains a strong cash generator, supporting investment in smoke-free expansion and shareholder returns.
5. Regulatory and Market Access Tailwinds
Positive regulatory momentum (e.g., new market access in the Middle East, EU minimum tax differentiation for smoke-free) underpins future growth, though illicit trade and regulatory risk remain material, especially in Europe and Indonesia.
Key Considerations
PMI’s Q2 2025 showcased the company’s ability to scale smoke-free profitably while defending legacy cash flows. The strategic focus is on leveraging category leadership, operational discipline, and regulatory engagement to drive sustainable growth.
Key Considerations:
- Smoke-Free Margin Leverage: Gross margin for smoke-free products now exceeds combustibles, with scale and mix driving accretion.
- U.S. Zyn Inflection: Full capacity and renewed promotions should drive H2 acceleration, but Q3 may see inventory normalization before a Q4 step-up.
- Combustible Volume Decline Managed: Expected 2% decline is in line with long-term trends, with pricing and mix offsetting volume pressure.
- Cost Savings and Capex Discipline: Over $1.2 billion in cost savings delivered toward a $2 billion target, with capex focused on expanding smoke-free infrastructure.
- Regulatory Developments: EU tax reform and illicit trade management remain critical watchpoints for future profit pools.
Risks
Key risks include regulatory uncertainty in Europe and the U.S., especially regarding the timing of FDA approval for IQOS ILUMA and potential changes to excise tax frameworks. Illicit trade growth, particularly in Indonesia and the EU, could erode legal market share and profit pools. Currency volatility, notably the Swiss franc’s impact on costs and intercompany flows, remains a headwind despite some translation benefit from a weaker U.S. dollar. Management’s ability to ramp Zyn commercial activity and sustain IQOS premiumization will be tested as competitive intensity rises.
Forward Outlook
For Q3 2025, PMI guided to:
- HTU (Heated Tobacco Unit) shipments of 38.5 to 39.5 billion
- Adjusted diluted EPS of $2.08 to $2.13, including a $0.05 currency tailwind
For full-year 2025, management raised guidance:
- Organic net revenue growth of 6% to 8%
- Organic operating income growth of 11% to 12.5%
- Currency-neutral adjusted diluted EPS growth of 11.5% to 13.5%
- Operating cash flow forecast raised to around $11.5 billion
Management cited continued smoke-free momentum, robust pricing, and margin improvement as key drivers, while flagging tougher H2 combustible comps and phasing effects from earlier device launches and Zyn restocking.
- H2 smoke-free growth expected to remain strong, with commercial activity ramping in the U.S. and new market rollouts in Europe and Asia.
- Combustible profit growth to moderate, but still positive due to pricing and efficiency.
Takeaways
PMI’s Q2 2025 execution demonstrates a successful pivot toward multi-category smoke-free profit growth, with legacy combustibles providing a resilient financial base.
- Smoke-Free Scale and Margin: Rapid growth in IQOS, Zyn, and Veve is now accretive to gross margin and operating income, validating the multi-category strategy.
- Combustible Cash Engine: Despite volume headwinds, pricing and efficiency keep the legacy business a strong cash contributor, funding transformation and dividends.
- H2 Watchpoints: Zyn’s U.S. acceleration, IQOS ILUMA FDA approval, and regulatory developments in the EU will determine the pace and durability of future growth.
Conclusion
Philip Morris International’s Q2 2025 results reinforce its transformation into a high-margin, multi-category nicotine business. With smoke-free momentum, disciplined capital allocation, and upgraded guidance, PMI is positioned for further earnings and cash flow growth, though regulatory and competitive risks must be closely monitored.
Industry Read-Through
PMI’s results signal a critical inflection for the global nicotine industry. The shift toward smoke-free, high-margin categories is accelerating, with multi-category portfolios and consumer switching becoming the new competitive frontier. Legacy tobacco players face mounting pressure to scale alternatives profitably, while regulatory frameworks and illicit trade dynamics will increasingly shape profit pools. For peers, the bar for innovation, operational discipline, and regulatory engagement is rising, and U.S. FDA approval timelines for next-generation products remain a sector-wide swing factor.